TG Therapeutics Announces Presentation Of Data For BRIUMVI At The 2023 European Committee For Treatment And Research In Multiple Sclerosis Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
TG Therapeutics, Inc. (NASDAQ:TGTX) has presented data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS) at the 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting. The data highlights the unique attributes of BRIUMVI and includes the first data from the ENHANCE trial evaluating patients who switch from an IV anti-CD20 antibody to BRIUMVI.
October 11, 2023 | 2:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TG Therapeutics' presentation of positive data from Phase 3 trials of BRIUMVI at a major conference could boost investor confidence and potentially impact the company's stock positively in the short term.
The presentation of positive data from Phase 3 trials at a major conference is a significant event for a biotech company like TG Therapeutics. This could lead to increased investor confidence in the company and its product, BRIUMVI, potentially leading to a positive impact on the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100